Most common adverse pregnancy outcome is spontaneous abortions affecting 10-15% pregnancies. Recurrent pregnancy loss (RPL) affects about 5% of women. High levels of homocysteine, termed hyperhomocysteinemia known to cause a number of pathologic processes in the venous and arterial vascular systems. A prospective study of 80 pregnant mothers booked at our hospital over a period of 18 months with history of unexplained RPL were included in the study and their serum homocysteine, Vitamin B12, serum Folic Acid levels were assessed. Hyperhomocysteinemia (>12 micromol/l) patients were treated with folic acid and vitamin B12 supplements irrespective of biochemical values of vitamin B12 and folic acid for 6 weeks and serum homocysteine, serum folic acid and serum vitamin B12 levels were levels were assessed again, post treatment. In our study, post vitamin supplementation, 76.25% patients showed reduction in serum homocysteine levels but 23.75% of those who initially had hyperhomocysteinemia continued to have hyperhomocysteinemia. At the beginning of the study, the mean serum homocysteine level was 14.43 ± 4.52 micromol/L. After 6 weeks of vitamin B12 and folic Acid supplementation, the mean value reduced to 10.42 ± 3 micromol/L with a difference of 4.01 and a statistically significant p value of < 0.001. At the beginning of the study, the mean serum vitamin B12 level was 328.03 ± 151.91 pg/mL. After 6 weeks of vitamin B12 and folic Acid supplementation, the mean value increased to 716.65 ± 224.8pg/mL with a difference of 388.63 and a statistically significant p value of < 0.001. At the beginning of the study, the mean serum folic acid level was 5.98 ± 2.24ng/mL. After6weeksofvitaminB12andfolicAcidsupplementation,themeanvalue increased to 9.05 ± 1.97ng/mL with a difference of 388.63 and a statistically significant p value of< 0.001. RPL with Hyperhomocysteinemia is associated with folic Acid and vitamin B12 deficiency. Vitamin supplementation to those with hyperhomocysteinemia, decreases homocysteine levels.